Abstract

<p>Plasma concentration for copanlisib (BAY 80-6946). Plasma concentration of copanlisib (BAY 80-6946) was measured in samples from nine patients collected on cycle 1 day 15 before infusion (pre-dose) and at 0.5, 1, 2, 4, 6, 8, and 24 hours after infusion. Eight patients received copanlisib 45 mg and one patient received 30 mg. The time to the maximum concentration of copanlisib when administered in combination with rucaparib ranged between 0.5 and 4 hours. The mean terminal half-life was 41.4 ± 56.7 hours. The mean clearance was 32,656 ± 18,164 mL/hour. These parameters are consistent with historical PK parameters of copanlisib.</p>

Related Publications

Publication Info

Year
2025
Type
article
Citations
0
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

0
OpenAlex
0
CrossRef

Cite This

André Souza, Matthew J. Hadfield, Shaolei Lu et al. (2025). Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). . https://doi.org/10.1158/2767-9764.30849280

Identifiers

DOI
10.1158/2767-9764.30849280

Data Quality

Data completeness: 66%